Resources with keywords: poxvirus

Levy V, Branzuela A, Hsieh K, et al.
The first reported clade Ib MPXV infection in the Americas was identified via electronic laboratory reporting in California in a U.S. traveler who returned from East Africa.

On November 18, 2024, the U.S. Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory about the first case of clade I mpox diagnosed in the United States.

CDC assessed the risk to the United States posed by the clade I mpox outbreak in the Democratic Republic of Congo and in countries in Central and Eastern Africa. Four travel-associated cases of clade Ib mpox have been confirmed in the United States—in California, Georgia, New Hampshire, and New York. Our risk assessment remains unchanged, since onward spread of clade I mpox has not occurred in the United States to date. The risk to the general population is assessed as low.

The high proportion of children with suspected mpox reported in the current outbreak is likely due to a number of factors, including spread within and between close households, younger population demographics in impacted countries, misdiagnosis of other diseases (such as measles), poor sanitary conditions, limited access to health services, and a high level of food insecurity and malnutrition.

Gigante CM, Takakuwa J, McGrath D, et al.
Tecovirimat is the first-line drug for treatment of orthopoxvirus infection (e.g., smallpox and mpox). Viral mutations that render the drug ineffective can develop during treatment.

This is a Health Alert Network (HAN) Health Update to provide additional information about the ongoing outbreak of clade I monkeypox virus (MPXV), the virus that causes mpox, in Central and Eastern Africa